Aardvark Therapeutics, Inc. Common Stock

10-Year Study

AARD.US · Healthcare · US · Common Stock

Executive Summary: Aardvark Therapeutics, Inc. Common Stock has compounded at -55.4% annually over the last 10 years, with a maximum drawdown of 72.1% and an annualized volatility of 1132.5%.

1Y CAGR
-55.3%
3Y CAGR
-55.4%
5Y CAGR
-55.4%
10Y CAGR
-55.4%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
72.1%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.05
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.07
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
125.0%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · +-62.0%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2026 · -62.0%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
0%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-1.0-3.8-69.832.4————————-62.0%
2025——-41.047.9-6.029.5-11.2-30.960.1-19.6-6.631.53.1%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 1132.5%. The dominant macroeconomic risk driver is VTI.US, accounting for 24.7% of variance. Idiosyncratic stock-specific factors contribute 0.0%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2025-02-0110000
2025-03-015899.450117831892
2025-04-018727.415553809897
2025-05-018201.099764336213
2025-06-0110620.581304006284
2025-07-019434.406912804398
2025-08-016520.031421838178
2025-09-0110439.905734485466
2025-10-018397.486252945797
2025-11-017839.74862529458
2025-12-0110310.290652003143
2026-01-0110204.241948153967
2026-02-019811.468970934799
2026-03-012961.5082482325215
2026-04-013919.87431264729
Annual Return Matrix
YearAnnual Return
2026-0.6198095238095238
Total Factor Risk
11.325120957411862
VTI.US Exposure
0.24698972414789336
VEA.US Exposure
-0.010525977152082651
VWO.US Exposure
0.0004870018872866045
QQQ.US Exposure
0.029953465331199972
VTV.US Exposure
-0.0484282132561067
IJR.US Exposure
-0.033920459935370274
QUAL.US Exposure
0.16472471539127884
SHV.US Exposure
0.04557827760860078
TLT.US Exposure
0.04944377237575081
LQD.US Exposure
0.06464293354374409
HYG.US Exposure
0.15682218209202756
GLD.US Exposure
0.027105448586794537
USO.US Exposure
0.012819032700761478
VNQ.US Exposure
0.06561938210278499
BTC-USD.CC Exposure
-0.001474261381595713
CPER.US Exposure
0.0005841413467167668
VIX.INDX Exposure
0.00009996769613887327
UUP.US Exposure
-0.0008007100834820796
TIP.US Exposure
0.23027957691969111
Idiosyncratic Exposure
7.79676243603258e-11
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
1132.5%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$93.8M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-31.6%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-54.6%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
71.3% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
1.00
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Aardvark Therapeutics, Inc. Common Stock a high-risk investment?

Aardvark Therapeutics, Inc. Common Stock (AARD.US) has an annualized volatility of 1132.5% and experienced a maximum drawdown of 72.1% over the last 10 years. Its primary macro risk driver is VTI.US.

What is the 10-year return of AARD.US?

Over the past 10 years, AARD.US has generated a Compound Annual Growth Rate (CAGR) of -55.4%. It has had a positive return in 0% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Aardvark Therapeutics, Inc. Common Stock

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest